title: Histaminergic control of mucosal repair in the small intestine.
abstract: The aim of the present paper was to summarize histamine-mediated repair of rat intestinal mucosa. To evaluate intestinal repair, we examined lipid transport (an index of intestinal mucosal function) after 15 minutes occlusion of the superior mesenteric artery. Rats were pretreated with alpha-fluoromethylhistidine (a suicide inhibitor of histidine decarboxylase, a synthesizing enzyme of histamine), H1-receptor antagonist (chlorpheniramine maleate), H2-antagonist (cimetidine), or H3-antagonist (thioperamide) before ischemia-reperfusion (I/R). Lipid transport to rat mesenteric lymph decreased significantly 24 hours after I/R in all groups tested compared to sham-treated rats. Lipid transport was restored 48 hours after I/R in the vehicle-pretreated control group. Lipid transport was not restored to the control level 48 hours after I/R in rats pretreated with H1-antagonist and a suicide inhibitor of histidine decarboxylase. In contrast, intestinal function was restored to the control level 48 hours after I/R in rats pretreated with H2- and H3-antagonists. These results support our previous findings that newly formed histamine after I/R plays an important role in mucosal recovery through H1-receptors.
authors.affiliation: Department of Internal Medicine, Saga Medical School, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Gotoh
authors.forename: S
authors.initials: S
authors.lastname: Ogata
authors.forename: S
authors.initials: S
authors.lastname: Tsunada
authors.forename: T
authors.initials: T
authors.lastname: Ohyama
authors.forename: A
authors.initials: A
authors.lastname: Ootani
authors.forename: K
authors.initials: K
authors.lastname: Okamoto
authors.forename: T
authors.initials: T
authors.lastname: Sakata
mesh_terms: D000818:Animals; D001692:Biological Transport; D002744:Chlorpheniramine / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006632:Histamine / Q000502:physiology*; D006633:Histamine Antagonists / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006640:Histidine Decarboxylase / Q000037:antagonists & inhibitors; D007413:Intestinal Mucosa / Q000098:blood supply* / Q000503:physiopathology*; D007511:Ischemia / Q000503:physiopathology*; D050356:Lipid Metabolism; D008196:Lymph / Q000378:metabolism; D008297:Male; D008762:Methylhistidines / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015424:Reperfusion
chemical_list: D004791:Enzyme Inhibitors; D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D008762:Methylhistidines; D010880:Piperidines; D002744:Chlorpheniramine; C028309:alpha-fluoromethylhistidine; D002927:Cimetidine; D006632:Histamine; D006640:Histidine Decarboxylase; C052075:thioperamide